tbuckley/cabot-search huggingface dataset:
Fetal Hemoglobin Rescues Ineffective Erythropoiesis in Sickle Cell Disease
Authors: Sara El Hoss, Sylvie Cochet, Auria Godard, Hongxia Yan, Michaël Dussiot, Giacomo Frati, Bénédicte Boutonnat-Faucher, Sandrine Laurance, Olivier Renaud, Laure Joseph, Annarita Miccio, Valentine Brousse, Mohandas Narla, Wassim El Nemer
Journal: Blood (2020)
Abstract 250: Acting Instructor
Authors: Huiliang Zhang, Nathan Alder, Wang Wang, Hazel Szeto, David Marcinek, Peter S Rabinovitch
Journal: Circulation Research (2020)

Rational: Aging-associated diseases, including cardiac dysfunction, are increasingly common in the population. However, the mechanisms of physiologic aging in general, and cardiac aging in particular, remain poorly understood. While effective medical interventions are available for some kinds of heart failure, one age-related impairment, diastolic dysfunction in Heart Failure with Preserved Ejection Fraction (HFpEF) is lacking a clinically effective treatment. Methods and Results: Using the pH indicator cpYFP in the model of naturally aging mice and rats, we show direct evidence of increased mitochondrial proton leak in aged heart mitochondria following a pH gradient stress. Furthermore, we identified Adenine Nucleotide Translocator 1 (ANT1) as mediating the increased proton permeability of old cardiomyocytes. Most importantly, acute (2 hours) in vitro treatment with the tetra-peptide drug SS-31 (elamipretide) reverses age-related excess proton entry, decreases the mitochondrial flash activity and mitochondrial permeability transition pore (mPTP) opening and rejuvenates mitochondrial function. Moreover, we show that SS-31 benefits the old mitochondria by direct association with ANT1 and stabilization of the mitochondrial ATP synthasome, leading to substantial reversal of diastolic dysfunction. Conclusion: Our results uncover excessive mitochondrial proton leak as a novel mechanism of age-related cardiac dysfunction and elucidate how SS-31 is able to reverse this clinically important complication of cardiac aging.
<i>In Situ</i> Vaccination in Lymphoma Using Photothermal Therapy with CpG Deoxynucleotide Coated Branched Gold Nanoparticles: Analysis of Tumor Growth and Immune Response in a Murine Xenograft Model
Authors: Adam Yuh Lin, Bongseo Choi, Taehoon Sim, Leo I. Gordon, Dong-Hyun Kim
Journal: Blood (2020)
Microenvironment in subchondral bone: predominant regulator for the treatment of osteoarthritis
Authors: Wenhui Hu, Yueqi Chen, Ce Dou, Shiwu Dong
Journal: Annals of the Rheumatic Diseases (2020)

Osteoarthritis (OA) is a degenerative joint disease in the elderly. Although OA has been considered as primarily a disease of the articular cartilage, the participation of subchondral bone in the pathogenesis of OA has attracted increasing attention. This review summarises the microstructural and histopathological changes in subchondral bone during OA progression that are due, at the cellular level, to changes in the interactions among osteocytes, osteoblasts, osteoclasts (OCs), endothelial cells and sensory neurons. Therefore, we focus on how pathological cellular interactions in the subchondral bone microenvironment promote subchondral bone destruction at different stages of OA progression. In addition, the limited amount of research on the communication between OCs in subchondral bone and chondrocytes (CCs) in articular cartilage during OA progression is reviewed. We propose the concept of ‘OC–CC crosstalk’ and describe the various pathways by which the two cell types might interact. Based on the ‘OC–CC crosstalk’, we elaborate potential therapeutic strategies for the treatment of OA, including restoring abnormal subchondral bone remodelling and blocking the bridge—subchondral type H vessels. Finally, the review summarises the current understanding of how the subchondral bone microenvironment is related to OA pain and describes potential interventions to reduce OA pain by targeting the subchondral bone microenvironment.
Abstract IA08: Tracking the impact of tumor mutations in the T cell differentiation landscape of lung cancer
Authors: Sergio A. Quezada
Journal: Cancer Research (2020)

Abstract Tumour mutational burden (TMB) predicts immunotherapy outcome in non-small cell lung cancer (NSCLC), consistent with immune recognition of tumour neoantigens. However, persistent antigen exposure is detrimental for T cell function. How TMB affects CD4 and CD8 T cell differentiation in untreated tumours and whether this affects patient outcomes is unknown. Here, we paired high-dimensional flow cytometry, exome, single-cell and bulk RNA sequencing from patients with resected, untreated NSCLC to examine these relationships. TMB was associated with compartment-wide T cell differentiation skewing, characterized by loss of TCF7-expressing progenitor-like CD4 T cells, and an increased abundance of dysfunctional CD8 and CD4 T cell subsets with strong phenotypic and transcriptional similarity to neoantigen-reactive CD8 T cells. A gene signature of redistribution from progenitor-like to dysfunctional states was associated with poor survival in lung and other cancer cohorts. Single-cell characterization of these populations informs potential strategies for therapeutic manipulation in NSCLC. Citation Format: Sergio A. Quezada. Tracking the impact of tumor mutations in the T cell differentiation landscape of lung cancer [abstract]. In: Proceedings of the AACR Virtual Special Conference on Tumor Heterogeneity: From Single Cells to Clinical Impact; 2020 Sep 17-18. Philadelphia (PA): AACR; Cancer Res 2020;80(21 Suppl):Abstract nr IA08.
Pre-Clinical Efficacy of Co-Targeting GFI1/KDM1A and BRD4 or JAK1/2 Against AML and Post-MPN Secondary AML Blast Progenitor Cells
Authors: Warren Fiskus, Christopher Peter Mill, Christine Birdwell, Bernardo H Lara, Prithviraj Bose, Lucia Masarova, Tapan M. Kadia, Joseph D. Khoury, Taghi Manshouri, Srdan Verstovsek, Kapil N. Bhalla
Journal: Blood (2020)
Urinary glycoproteins associated with aggressive prostate cancer
Authors: Mingming Dong, T. Mamie Lih, Shao-Yung Chen, Kyung-Cho Cho, Rodrigo Vargas Eguez, Naseruddin Höti, Yangying Zhou, Weiming Yang, Leslie Mangold, Daniel W. Chan, Zhen Zhang, Lori J. Sokoll, Alan Partin, Hui Zhang
Journal: Theranostics (2020)

Background: There is an urgent need for the detection of aggressive prostate cancer. Glycoproteins play essential roles in cancer development, while urine is a noninvasive and easily obtainable biological fluid that contains secretory glycoproteins from the urogenital system. Therefore, here we aimed to identify urinary glycoproteins that are capable of differentiating aggressive from non-aggressive prostate cancer. Methods: Quantitative mass spectrometry data of glycopeptides from a discovery cohort comprised of 74 aggressive (Gleason score ≥8) and 68 non-aggressive (Gleason score = 6) prostate cancer urine specimens were acquired via a data independent acquisition approach. The glycopeptides showing distinct expression profiles in aggressive relative to non-aggressive prostate cancer were further evaluated for their performance in distinguishing the two groups either individually or in combination with others using repeated 5-fold cross validation with logistic regression to build predictive models. Predictive models showing good performance from the discovery cohort were further evaluated using a validation cohort. Results: Among the 20 candidate glycoproteins, urinary ACPP outperformed the other candidates. Urinary ACPP can also serve as an adjunct to serum PSA to further improve the discrimination power for aggressive prostate cancer (AUC= 0.82, 95% confidence interval 0.75 to 0.89). A three-signature panel including urinary ACPP, urinary CLU, and serum PSA displayed the ability to distinguish aggressive prostate cancer from non-aggressive prostate cancer with an AUC of 0.86 (95% confidence interval 0.8 to 0.92). Another three-signature panel containing urinary ACPP, urinary LOX, and serum PSA also demonstrated its ability in recognizing aggressive prostate cancer (AUC=0.82, 95% confidence interval 0.75 to 0.9). Moreover, consistent performance was observed from each panel when evaluated using a validation cohort. Conclusion: We have identified glycopeptides of urinary glycoproteins associated with aggressive prostate cancer using a quantitative mass spectrometry-based glycoproteomic approach and demonstrated their potential to serve as noninvasive urinary glycoprotein biomarkers worthy of further validation by a multi-center study.
Alterations in the Duodenal Fluid Microbiome of Patients With Pancreatic Cancer
Authors: Shiro Kohi, Anne Macgregor-Das, Mohamad Dbouk, Takeichi Yoshida, Miguel Chuidian, Toshiya Abe, Michael Borges, Anne Marie Lennon, Eun Ji Shin, Marcia Irene Canto, Michael Goggins
Journal: Clinical Gastroenterology and Hepatology (2020)

The tumor microbiome of patients with pancreas ductal adenocarcinoma (PDAC) includes bacteria normally present in the upper gastrointestinal tract. If the predominant source of intratumoral bacteria in patients with PDAC is retrograde migration from the duodenum, duodenal fluid could be a representative biospecimen for determining microbiome profiles of patients with PDAC or at risk of developing PDAC.We performed a case-control study comparing bacterial and fungal (16S and 18S rRNA) profiles of secretin-stimulated duodenal fluid collections from 308 patients undergoing duodenal endoscopy including 134 normal pancreas control subjects, 98 patients with pancreatic cyst(s) and 74 patients with PDAC.Alterations in duodenal fluid microbiomes with diminished alpha diversity were significantly associated with age >70 and proton pump inhibitor use. Patients with PDAC had significantly decreased duodenal microbial alpha diversity compared with age-matched control subjects with normal pancreata and those with pancreatic cyst(s). There was evidence of enrichment of Bifidobacterium genera in the duodenal fluid of patients with PDAC compared with control subjects and those with pancreatic cyst(s). There were also enrichment of duodenal fluid Fusobacteria and Rothia bacteria among patients with PDAC with short-term survival. Duodenal fluid microbiome profiles were not significantly different between control subjects and patients with pancreatic cyst(s).Patients with PDAC have alterations in their duodenal fluid microbiome profiles compared with patients with pancreatic cysts and those with normal pancreata. ClinicalTrials.gov, Number: NCT02000089.
The Clinical Relevance of Residual, Persistent and Elongated Abnormal Sized Nodes By Longest Diameter (LDi) in Patients (pts) with Chronic Lymphocytic Leukemia (CLL), Otherwise in a Complete Remission (CR)
Authors: Jayant Narang, Surabhi Bajpai, Rudresh Rajnikant Jarecha, Christiana Caplan, Dana Macdonald, Gabriele Padrella, Manish Sharma, Bruce D. Cheson
Journal: Blood (2020)
Iron Therapy Induced Leukopenia
Authors: Hussam A Almasri, Ashraf Tawfiq Soliman, Vincenzo Desanctis, Arwa E Alsaud, Ruoa Alhashimy, Mona M Babikir, Rita Wafik Ahmad, Majd M Aldwairi, Mohammad N Kloub, Shaima Ahmed, Mustafa A Al-Tikrity, Mahmoud S Eisa, Mohamed A Yassin
Journal: Blood (2020)
Pseudo-Allogeneic CAR-T Therapy after Allogeneic Stem Cell Transplantation in Relapsed/Refractory B-Cell NHL
Authors: Jonathan Siglin, Forat Lutfi, Ali Bukhari, Noa G. Holtzman, Dong Won Kim, Moaath Mustafa Ali, Aaron P. Rapoport, Saurabh Dahiya
Journal: Blood (2020)
A Multi-Center, Open Label, Phase I/II Study to Assess the Safety and Efficacy of Tenalisib Given in Combination with Romidepsin in Patients with Relapsed/Refractory T-Cell Lymphoma
Authors: Swami P. Iyer, Auris Huen, Bradley Haverkos, Weiyun Z. Ai, Craig Okada, Timothy M. Kuzel, Mary Jo Lechowicz, Juan Pablo Alderuccio, Ann Mohrbacher, Don A. Stevens, Ryan A. Wilcox, Tatyana A. Feldman, Suchitra Sundaram, Deepa Jagadeesh, Nishitha Reddy, Kasi Viswanath Routhu, Prajak Barde, Ajit Mohanchandran Nair
Journal: Blood (2020)
Immune Evasion Phenotype Is Common in Richter Transformation Diffuse Large B-Cell Lymphoma and Correlates with CD30 Expression
Authors: Siba El Elhussein, L. Jeffrey Medeiros, Kirill A. Lyapichev, Stephen K. Gruschkus, Peng Wei, Ellen Schlette, Warren Fiskus, Rashmi Kanagal-Shamanna, Sanam Loghavi, Hong Yang, Shaoying Li, Jie Xu, Zhenya Tang, Beenu Thakral, Nitin Jain, William G. Wierda, Keyur Patel, Kapil N. Bhalla, Joseph D. Khoury
Journal: Blood (2020)
Longitudinal Serological Response to Sars-COV-2 in Patients Affected By Hematologic Diseases
Authors: Chiara Cattaneo, Valeria Cancelli, Chiara Pagani, Alessandra Tucci, Giuseppe Rossi, Luisa Imberti, Alessandra Sottini, Kerry Dobbs, Elana Shaw, Luigi D. Notarangelo, Jeffrey Cohen, Peter Burbelo
Journal: Blood (2020)
Lipopolysaccharide-Mediated Chronic Inflammation Promotes Tobacco Carcinogen–Induced Lung Cancer and Determines the Efficacy of Immunotherapy
Authors: Chia-Hsin Liu, Zhong Chen, Kong Chen, Fu-Tien Liao, Chia-En Chung, Xiaoping Liu, Yu-Chun Lin, Phouthone Keohavong, George D. Leikauf, Yuanpu Peter Di
Journal: Cancer Research (2020)

Chronic obstructive pulmonary disease (COPD) is an inflammatory disease that is associated with increased risk of lung cancer.
Real World Efficacy Evaluation of Branded and Copy Imatinib in Chronic Myeloid Leukemia: A Retrospective Multicentric Study from Argentina
Authors: Ana Ines Varela, Georgina Bendek, Carolina Pavlovsky, Maria Josefina Freitas, Veronica Ventriglia, Alicia Enrico, Maria Elisa Riva, Mariel Ana Perez, Romina Mariano, Luis Beligoy, Maria Pagani, Ricardo Khalil Tannuri, Irene Larripa, Raquel Bengio, Francisca Rojas, Dardo Riveros, Mariana Raquel Debus, Erica Franceschi, Maria Victoria Osycka, Miguel A. Pavlovsky, Beatriz Moiraghi
Journal: Blood (2020)
Preclinical Characterization of BCX9930, a Potent Oral Complement Factor D Inhibitor, Targeting Alternative Pathway-Mediated Diseases Including Paroxysmal Nocturnal Hemoglobinuria (PNH)
Authors: Xilin Chen, Xiaogang Cheng, Qingde Liu, Saritha Muppa, Cynthia Parker, Fugang Zhu, Krishnan Raman, Pravin L Kotian, Yarlagadda S. Babu
Journal: Blood (2020)
Efficacy and Safety of Recombinant Thrombombomodulin for the Prophylaxis of Vaso-Occlusive Complications in Allogenic Hematopoietic Stem Cell Transplantation : A Systematic Review and Meta-Analysis
Authors: Richi Kashyap, Muhammad Ashar Ali, Taaha Muddassir Mirza, Anum Javaid, Aniqa Raheem, Rohail Gul, Muhammad Tayyeb, Muhammad Yasir Anwar, Abdul Jabbar Dar, Qasim Khurshid, Karun Neupane, Faiz Anwer
Journal: Blood (2020)
Distinct Polysaccharide Utilization Determines Interspecies Competition between Intestinal Prevotella spp.
Authors: Eric J.C. Gálvez, Aida Iljazovic, Lena Amend, Till Robin Lesker, Thibaud Renault, Sophie Thiemann, Lianxu Hao, Urmi Roy, Achim Gronow, Emmanuelle Charpentier, Till Strowig
Journal: Cell Host & Microbe (2020)
Treatment Guided By Next Generation Functional Drug Screening Provides Clinical Benefit in Advanced Aggressive Hematological Malignancies: Final Evaluation of the Open Label, Single Arm Exalt Trial
Authors: Christoph Kornauth, Tea Pemovska, Gregory Ian Vladimer, Günther Bayer, Michael Bergmann, Sandra Eder, Ruth Eichner, Harald Esterbauer, Ruth Exner, Verena Felsleitner-Hauer, Maurizio Forte, Alexander Gaiger, Hildegard T. Greinix, Wolfgang Gstöttner, Marcus Hacker, Alexander Hauswirth, Tim Heinemann, Daniel Heintel, Mir Ali Reza Hoda, Ulrich Jaeger, Lukas Kazianka, Lukas Kenner, Barbara Kiesewetter, Nikolaus Krall, Trang Le, Simone Lubowitzki, Marius E Mayerhoefer, Elisabeth Menschel, Olaf Merkel, Katsuhiro Miura, Leonhard Muellauer, Peter Neumeister, Thomas Noesslinger, Katharina Ocko, Leopold Öhler, Michael Panny, Alexander Pichler, Edit Anna Porpaczy, Gerald Prager, Markus Raderer, Robin Ristl, Reinhard Ruckser, Julius Salamon, Ana-Iris Schiefer, Ann-Sofie Schmolke, Ilse Schwarzinger, Edgar Selzer, Cathrin Skrabs, Wolfgang R. Sperr, Ismet Srndic, Renate Thalhammer, Peter Valent, Emiel van der Kouwe, Katrina Vanura, Stefan Vogt, Cora Waldstein, Dominik Wolf, Christoph Zielinski, Ingrid Simonitsch-Klupp, Giulio Superti-Furga, Berend Snijder, Philipp B. Staber
Journal: Blood (2020)
Therapeutics Targeting Mutant KRAS
Authors: Kyaw Z. Thein, Amadeo B. Biter, David S. Hong
Journal: Annual Review of Medicine (2020)

Aberrations in rat sarcoma (RAS) viral oncogene are the most prevalent and best-known genetic alterations identified in human cancers. Indeed, RAS drives tumorigenesis as one of the downstream effectors of EGFR activation, regulating cellular switches and functions and triggering intracellular signaling cascades such as the MAPK and PI3K pathways. Of the three RAS isoforms expressed in human cells, all of which were linked to tumorigenesis more than three decades ago, KRAS is the most frequently mutated. In particular, point mutations in KRAS codon 12 are present in up to 80% of KRAS-mutant malignancies. Unfortunately, there are no approved KRAS-targeted agents, despite decades of research and development. Recently, a revolutionary strategy to use covalent allosteric inhibitors that target a shallow pocket on the KRAS surface has provided new impetus for renewed drug development efforts, specifically against KRASG12C. These inhibitors, such as AMG 510 and MRTX849, show promise in early-phase studies. Nevertheless, combination strategies that target resistance mechanisms have become vital in the war against KRAS-mutant tumors.
Pharmacologic Inhibition of B Cell-Receptor-Associated Kinases with CG-806 Induces Apoptosis and Metabolic Reprogramming in Aggressive Non-Hodgkin Lymphoma (NHL) Models
Authors: Elana Thieme, Vi Lam, Nur Bruss, Fei Xu, Stephen E Kurtz, Jeffrey W. Tyner, Alexey Danilov, Tingting Liu
Journal: Blood (2020)
Results of a Phase 1 Open Label Dose Escalation Trial of AB-205 (Allogeneic Engineered Endothelial Cell Therapy) in Adults with Lymphoma Undergoing High-Dose Therapy and Autologous Hematopoietic Cell Transplantation (HDT-AHCT)
Authors: Michael Scordo, Lihua E Budde, Mehrdad Abedi, Carolyn Mulroney, Bita Fakhri, Attaphol Pawarode, Bhagirathbhai Dholaria, Edward Kavalerchik, Sanjay K. Aggarwal, Muzaffar H. Qazilbash, Paul Finnegan, Sergio A. Giralt
Journal: Blood (2020)
Hematological Indices Reference Intervals for Healthy Arab Population in Qatar: Effect of Age, Gender, Geographic Location and ABO Blood Group
Authors: Mohamed A Yassin, Ashraf Tawfiq Soliman, Feryal Abbas, Abdulqadir Jeprel Nashwan, Mahmood B Aldapt, Mohammad Abdul-Jaber Abdulla, Saloua Hmissi, Ans Almami, Ezzeddin Ibrahim, Aasir Suliman, Khadra S Yassin, Niloofar Allahverdi, Shehab F Mohamed
Journal: Blood (2020)
Selinexor, Lenalidomide and Dexamethasone (SRd) for Patients with Relapsed/Refractory and Newly Diagnosed Multiple Myeloma
Authors: Darrell J White, Richard LeBlanc, Muhamed Baljevic, Nizar J. Bahlis, Suzanne Lentzsch, Christopher P. Venner, Cristina Gasparetto, Christine I Chen, Brea Lipe, Sascha A Tuchman, Heather J Sutherland, Rami Kotb, Michael Sebag, Natalie S. Callander, William I Bensinger, Adriana C Rossi, Heidi Sheehan, Dane Van Domelen, Tianjun Zhou, Kai Kazuharu, Jatin Shah, Sharon Shacham, Michael G Kauffman, Gary J. Schiller
Journal: Blood (2020)
Venous Thromboembolism Associated With Pregnancy
Authors: Katherine M. Nichols, Stanislav Henkin, Mark A. Creager
Journal: Journal of the American College of Cardiology (2020)

Venous thromboembolism (VTE), composed of pulmonary embolism and deep venous thrombosis, is a significant cause of maternal mortality in the developed world. Normal physiological changes of pregnancy increase coagulability, which is compounded by patient-inherited and acquired risk factors. Depending on these risks and peripartum stage, the benefits of thromboprophylaxis can outweigh potential side effects. Diagnosis requires cautious clinical acumen because many symptoms of normal pregnancy mimic those of VTE and algorithmic tools used in the nonpregnant population are not equally applicable. Choice of imaging technique must account for potential risk to the fetus and altered test accuracy (sensitivity and specificity) in the setting of pregnancy. When VTE is diagnosed, anticoagulation is the backbone of treatment, with more advanced therapies being options for those with right ventricular dysfunction or unstable hemodynamics. Overall, pregnancy-associated VTE is complex, and management decisions should be individualized and informed by patient preferences.
Abstract 13446: Use of Sodium-Glucose Cotransporter 2 Inhibitors for Diuretic Resistance in Acute Decompensated Heart Failure Are Associated With Improved Diuretic Response
Authors: Matthew Griffin, Ralph J Riello, Oksana Kucher, Juan Ivey-Miranda, Veena S Rao, Devin Mahoney, Megan L Baker, Jack McCormick, Jeffrey M Testani
Journal: Circulation (2019)

Introduction: Sodium glucose cotransporter 2 inhibitors (SGLT-2is), originally developed as antihyperglycemics, have shown promising signals for decreasing heart failure hospitalization. This effec...
Diagnostic Work-up of Pulmonary Hypertension in Non Transfusion Dependent Thalassemia Patients: Pathophysiologichal Mechanisms and Clinical Implications
Authors: Marta Mancarella, Irene Motta, Irene Rota, Margherita Migone De Amicis, Alessia Marcon, Marta Ferraresi, Marianna Giuditta, Giovanna Graziadei, Maria Domenica Cappellini, Marco Vicenzi
Journal: Blood (2020)
The Influence of Personalized 2-Year Physiotherapy on Musculoskeletal Health and Quality of Life in Severe Hemophilia Patients with Inhibitor - Interim Analysis after 1 Year of the Program
Authors: Maria Helena Podolak-Dawidziak, Janusz Zawilski, Mariola Bober, Ewa Stefanska-Windyga, Anna Buczma, Iwona Prajs
Journal: Blood (2020)
Spleen and Symptom Responses of JAK Inhibitors in Myelofibrosis; A Systematic Review of Phase 2 and 3 Trials
Authors: Muhammad Ans Sharif, Muhammad Salman Faisal, Yazan Samhouri, Laila Hashim, Muhammad Yasir, Muhammad Yasir Anwar, Ali Younas Khan, Moazzam Shahzad, Anum Javaid, Muhammad Aadil Rahman, Faiz Anwer, Salman Fazal
Journal: Blood (2020)
LAWN MOWER VS. LEFT VENTRICULAR ASSIST DEVICE: A CASE OF TRAUMATIC CORONARY INJURY
Authors: Vishal Rao, Marat Fudim, Andrew Griffin, Jennifer Rymer, William Schuyler Jones, Lynne H. Koweek, Tony P. Smith, Daniele Marin, Adam DeVore
Journal: Journal of the American College of Cardiology (2020)
Ultrasound imaging of congestion in heart failure: examinations beyond the heart
Authors: Pierpaolo Pellicori, Elke Platz, Jeroen Dauw, Jozine M. ter Maaten, Pieter Martens, Emanuele Pivetta, John G.F. Cleland, John J.V. McMurray, Wilfried Mullens, Scott D. Solomon, Faiez Zannad, Luna Gargani, Nicolas Girerd
Journal: European Journal of Heart Failure (2020)
Preclinical Evaluation of ALLO-605, an Allogeneic BCMA Turbocar TTM Cell Therapy for the Treatment of Multiple Myeloma
Authors: Cesar Sommer, Regina Lin, Janette Sutton, Trevor Bentley, Duy Nguyen, Hayung Yoon, Melinda Au, Diego Vargas-Inchaustegui, Hsin-Yuan Cheng, Tom Van Blarcom, Siler Panowski, Barbra Sasu
Journal: Blood (2020)